New PD-1/PD-L1 Inhibitors

Cat.No. Product Name Information
A2002 Nivolumab Nivolumab is a genetically engineered, fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities.
A2004 Atezolizumab Atezolizumab is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1.
A2005 Pembrolizumab Pembrolizumab is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities.
S8158 PD-1/PD-L1 Inhibitor 3 PD-1/PD-L1 Inhibitor 3(Programmed Death-1/Programmed Death-Ligand 1 Inhibitor 3)is a Macrocyclic inhibitor of PD-1/PD-L1 interaction with IC50 of 5.6 nM
All PD-1/PD-L1 Inhibitors